Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov:193:114809.
doi: 10.1016/j.bcp.2021.114809. Epub 2021 Oct 19.

Pathogenic mitochondrial dysfunction and metabolic abnormalities

Affiliations
Free article
Review

Pathogenic mitochondrial dysfunction and metabolic abnormalities

Walter H Moos et al. Biochem Pharmacol. 2021 Nov.
Free article

Abstract

Herein we trace links between biochemical pathways, pathogenesis, and metabolic diseases to set the stage for new therapeutic advances. Cellular and acellular microorganisms including bacteria and viruses are primary pathogenic drivers that cause disease. Missing from this statement are subcellular compartments, importantly mitochondria, which can be pathogenic by themselves, also serving as key metabolic disease intermediaries. The breakdown of food molecules provides chemical energy to power cellular processes, with mitochondria as powerhouses and ATP as the principal energy carrying molecule. Most animal cell ATP is produced by mitochondrial synthase; its central role in metabolism has been known for >80 years. Metabolic disorders involving many organ systems are prevalent in all age groups. Progressive pathogenic mitochondrial dysfunction is a hallmark of genetic mitochondrial diseases, the most common phenotypic expression of inherited metabolic disorders. Confluent genetic, metabolic, and mitochondrial axes surface in diabetes, heart failure, neurodegenerative disease, and even in the ongoing coronavirus pandemic.

Keywords: Biochemical pathways; Diseases; Disorders; Dysfunction; Homeostasis; Metabolic abnormalities; Mitochondrial diseases; Pathogenesis; Pathogenesis and pathogenic drivers; Physiological networks; Reprogramming; Therapeutics.

PubMed Disclaimer

Publication types